Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors
暂无分享,去创建一个
K. Shokat | Roman K. Thomas | M. Peifer | F. Leenders | J. Wolf | M. Sos | R. Zahedi | K. Gevaert | R. Buettner | P. Knowles | N. McDonald | V. Tischler | J. Brägelmann | J. Diebold | J. Heuckmann | S. Kast | Dennis Plenker | A. Richters | O. Gautschi | G. Pall | Julian Engel | M. Riedel | M. A. Dammert | C. Lorenz | A. Scheel | Oliver Pagel | F. Mrugalla | R. Chauhan | D. Schütte | M. Keul | Y. Alber | M. Aerts | Mike Bührmann | J. Stark | Yanrui Song | Rakhee Chauhan
[1] Ross Camidge,et al. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Lauren L. Ritterhouse,et al. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. , 2016, Cancer discovery.
[3] P. Stephens,et al. Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] S. Kast,et al. Designing molecular complexes using free-energy derivatives from liquid-state integral equation theory , 2016, Journal of physics. Condensed matter : an Institute of Physics journal.
[5] K. Hess,et al. Safety, toxicity and activity of multi-kinase inhibitor vandetanib in combination with everolimus in advanced solid tumors. , 2016 .
[6] J. Mesirov,et al. The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .
[7] S. Knapp,et al. The ins and outs of selective kinase inhibitor development. , 2015, Nature chemical biology.
[8] Jochen Heil,et al. Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach. , 2015, Journal of medicinal chemistry.
[9] J. Wery,et al. Abstract 3581: Rapid conversion to resistance, of a colon PDX with ret-fusion, by ponatinib treatment could potentially be attributed to the introduction of the gate keeper mutation V804M , 2015 .
[10] B. Admire,et al. Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology. , 2015, Angewandte Chemie.
[11] M. Ladanyi,et al. Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers. , 2015 .
[12] Jochen Heil,et al. 3D RISM theory with fast reciprocal-space electrostatics. , 2015, The Journal of chemical physics.
[13] Minsoo Song. Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer. , 2015, Journal of medicinal chemistry.
[14] F. Cappuzzo,et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.
[15] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[16] H. Sakamoto,et al. Alectinib Shows Potent Antitumor Activity against RET-Rearranged Non–Small Cell Lung Cancer , 2014, Molecular Cancer Therapeutics.
[17] T. Clackson,et al. Abstract 2726: RET fusions identified in colorectal cancer PDX models are sensitive to the potent RET inhibitor ponatinib , 2014 .
[18] James T. Webber,et al. Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. , 2014, Cell reports.
[19] Matthew Meyerson,et al. Targeted genomic rearrangements using CRISPR/Cas technology , 2014, Nature Communications.
[20] I. Petersen,et al. CD74-NRG1 fusions in lung adenocarcinoma. , 2014, Cancer discovery.
[21] F. Yakes,et al. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. , 2013, Thyroid : official journal of the American Thyroid Association.
[22] I. Plaza-Menacho,et al. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase , 2013, Molecular and Cellular Endocrinology.
[23] Robert Gentleman,et al. Software for Computing and Annotating Genomic Ranges , 2013, PLoS Comput. Biol..
[24] Yutaka Suzuki,et al. Identification of a lung adenocarcinoma cell line with CCDC6‐RET fusion gene and the effect of RET inhibitors in vitro and in vivo , 2013, Cancer science.
[25] M. Ladanyi,et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. , 2013, Cancer discovery.
[26] S. Aebi,et al. A patient with lung adenocarcinoma and RET fusion treated with vandetanib. , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[27] M. Borrello,et al. RET inhibition: implications in cancer therapy , 2013, Expert opinion on therapeutic targets.
[28] R. Zahedi,et al. Protein carbamylation: In vivo modification or in vitro artefact? , 2013, Proteomics.
[29] F. Pociot,et al. TiSH--a robust and sensitive global phosphoproteomics strategy employing a combination of TiO2, SIMAC, and HILIC. , 2012, Journal of proteomics.
[30] Kevan M. Shokat,et al. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology , 2012, Nature.
[31] Sarat Chandarlapaty,et al. Negative feedback and adaptive resistance to the targeted therapy of cancer. , 2012, Cancer discovery.
[32] Yuki Togashi,et al. RET, ROS1 and ALK fusions in lung cancer , 2012, Nature Medicine.
[33] Doron Lipson,et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies , 2012, Nature Medicine.
[34] Yasushi Totoki,et al. KIF5B-RET fusions in lung adenocarcinoma , 2012, Nature Medicine.
[35] Albert Sickmann,et al. Systematic and quantitative comparison of digest efficiency and specificity reveals the impact of trypsin quality on MS-based proteomics. , 2012, Journal of proteomics.
[36] T. Köcher,et al. Universal and confident phosphorylation site localization using phosphoRS. , 2011, Journal of proteome research.
[37] Mindy I. Davis,et al. Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.
[38] William Pao,et al. ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors , 2011, Clinical Cancer Research.
[39] M. Ratain,et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] T. Clackson,et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. , 2009, Cancer cell.
[41] Laura Tolosi,et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. , 2009, The Journal of clinical investigation.
[42] William Stafford Noble,et al. Improvements to the percolator algorithm for Peptide identification from shotgun proteomics data sets. , 2009, Journal of proteome research.
[43] C. Sander,et al. V600EBRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway , 2009, Proceedings of the National Academy of Sciences.
[44] S. Salzberg,et al. TopHat: discovering splice junctions with RNA-Seq , 2009, Bioinform..
[45] Arvin C Dar,et al. Small molecule recognition of c-Src via the Imatinib-binding conformation. , 2008, Chemistry & biology.
[46] Yu Xue,et al. GPS 2.0, a Tool to Predict Kinase-specific Phosphorylation Sites in Hierarchy *S , 2008, Molecular & Cellular Proteomics.
[47] M. Meyerson,et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.
[48] P. A. Harris,et al. Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors. , 2007, Journal of medicinal chemistry.
[49] Svend Kjær,et al. Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain* , 2006, Journal of Biological Chemistry.
[50] Andrew T. Fenley,et al. Analytical electrostatics for biomolecules: beyond the generalized Born approximation. , 2006, The Journal of chemical physics.
[51] M. Santoro,et al. BAY 43-9006 inhibition of oncogenic RET mutants. , 2006, Journal of the National Cancer Institute.
[52] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[53] A. Ryan,et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors , 2004, Oncogene.
[54] M. Daly,et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.
[55] G. Daley,et al. Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL , 2003, Cell.
[56] F. Hirata,et al. Three-dimensional density profiles of water in contact with a solute of arbitrary shape: a RISM approach , 1998 .
[57] Benoît Roux,et al. An Integral Equation To Describe the Solvation of Polar Molecules in Liquid Water , 1997 .
[58] W. L. Jorgensen,et al. Comparison of simple potential functions for simulating liquid water , 1983 .
[59] T. Kohno,et al. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. , 2017, The Lancet. Respiratory medicine.
[60] J. Mesirov,et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.
[61] R. Zahedi,et al. Fast, efficient, and quality-controlled phosphopeptide enrichment from minute sample amounts using titanium dioxide. , 2014, Methods in molecular biology.
[62] Y. Humblet,et al. An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[63] C. Eyers. Universal sample preparation method for proteome analysis , 2009 .
[64] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.